Form 4: Enanta Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Director Terry Vance acquired 15,700 stock options in Enanta Pharmaceuticals on March 6, 2024.
Summary
- Terry Vance, a director of Enanta Pharmaceuticals, acquired 15,700 stock options on March 6, 2024.
- The exercise price of these options is $15.66.
- The options become exercisable monthly over one year, starting March 6, 2024, with the final installment vesting before the 2025 annual meeting of stockholders.
- The options expire on March 6, 2034.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, so it doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.
Stakeholder Impact
- The transaction could have a minor impact on shareholders by slightly diluting equity if the options are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of transaction: Director Terry Vance acquired 15,700 stock options. |
| 03/06/2024 | Options become exercisable monthly over one year, starting from this date. |
| 03/06/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.